Health Technology Assessment

All Items

• COVID-19 impact on the decision process of the Italian Medicine Agency: a quantitative assessment

  Beatrice Canali, Laura Candelora, Francesca Fiorentino, Tom Halmos, Paola La Malfa, Francesca Massara, Chiara Vassallo, Duccio Urbinati

  46-52

  DOI: https://doi.org/10.33393/grhta.2023.2560

• Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy

  Francesca Fiorentino, Paolo Di Rienzo

  29-39

  DOI: https://doi.org/10.33393/grhta.2023.2507

• Cost-effectiveness of IMI/CIL/REL for the treatment of carbapenem non-susceptible Gram-negative bacterial infections

  Martina Paoletti, Andrea Marcellusi, Joe Yang, Francesco Saverio Mennini

  18-28

  DOI: https://doi.org/10.33393/grhta.2023.2488

• Budget Impact analysis of a new system of care in Parkinson’s disease patients

  Chiara Bini, Francesco Saverio Mennini, Andrea Marcellusi, Martina Paoletti, Carlo Tomino

  91-98

  DOI: https://doi.org/10.33393/grhta.2022.2413

• Disability weights for castration-resistant prostate cancer: an empirical investigation

  Ludovica Borsoi, Oriana Ciani, Rocco De Vivo, Giorgio Ivan Russo, Marcello Scarcia, Chiara De Fino, Patrizia Beccaglia, Irene Luccarini

  146-154

  DOI: https://doi.org/10.33393/grhta.2022.2431

• Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy

  Giuseppe Pompilio, Davide Integlia

  138-145

  DOI: https://doi.org/10.33393/grhta.2022.2474

• Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain

  Prof. Dr. Jaime Rodríguez Quintosa, Dr. Cintia Cristina Ago, Dr. Antoni Sicras Mainar, Dr. Renata Villoro, Dr. Inés Pérez-Román

  133-137

  DOI: https://doi.org/10.33393/grhta.2022.2439

• Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis

  Gian Domenico Sebastiani, Marta Mosca, Roberto Ravasio, Pietro Brambilla, Paola Raimondo, Andrea Doria

  123-132

  DOI: https://doi.org/10.33393/grhta.2022.2470

• Economic evaluation of treosulfan in patients undergoing allogeneic haematopoietic stem cell transplantation

  Chiara Bini, Martina Paoletti, Andrea Marcellusi, Carlo Tomino, Francesco Saverio Mennini

  105-116

  DOI: https://doi.org/10.33393/grhta.2022.2412

• Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

  Margarita Majem, Rosa Álvarez, Ana Laura Ortega, Lucía Ruiz de Alda, Rocío Gordo, J Francisco García, Yoana Ivanova-Markova, Almudena González-Domínguez, Raquel Sánchez San Cristóbal, Federico Rojo

  82-90

  DOI: https://doi.org/10.33393/grhta.2022.2449

• The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study

  Arianna Bertolani, Roberto Ravasio, Paola Raimondo, Claudio Jommi

  73-81

  DOI: https://doi.org/10.33393/grhta.2022.2415

• Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis

  Filippo Rumi, Michele Basile, Americo Cicchetti, Rosario Contiguglia, Antonella Pentassuglia, Alessandro Oliva, Gianenrico Senna, Marco Bonavia, Francesco Scarpelli, Marco Benvenuto

  58-67

  DOI: https://doi.org/10.33393/grhta.2022.2290

• Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP)

  Francesco Saverio Mennini, Martina Paoletti, Chiara Bini, Andrea Marcellusi, Marco Falcone, Massimo Andreoni

  45-57

  DOI: https://doi.org/10.33393/grhta.2022.2287

• Distribution methods of ostomy and incontinence aids in the Italian healthcare setting: an evaluation questionnaire and social burden of direct distribution

  Filippo Rumi, Francesca Orsini, Vincenzo Falabella, Pier Raffaele Spena, Americo Cicchetti

  36-44

  DOI: https://doi.org/10.33393/grhta.2022.2292

• Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations

  Giuseppe Pompilio, Alessandro Morabito, Diego L. Cortinovis, Davide Integlia

  22-29

  DOI: https://doi.org/10.33393/grhta.2022.2351

• A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

  Néboa Zozaya, Teresa Caballero, Teresa González-Quevedo, Pedro Gamboa Setien, M. Ángeles González, Ramón Jódar, José Luis Poveda-Andrés, Encarna Guillén-Navarro, Agustín Rivero Cuadrado, Álvaro Hidalgo-Vega

  14-21

  DOI: https://doi.org/10.33393/grhta.2022.2333

• Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update

  Andrea Aiello, Maria E. Mancuso, Serena Leone, Letizia Rossi, Lorenzo Cioni, Cristina Teruzzi

  9-13

  DOI: https://doi.org/10.33393/grhta.2022.2331

• Use of a maturity model for facilitating the introduction of CAR T-cell therapy—Results of the START CAR-T project

  Stefania Bramanti, Matteo Carrabba, Alice Di Rocco, Elena Fabris, Luca Gastaldi, Paolo Locatelli, Maria Chiara Tisi

  1-8

  DOI: https://doi.org/10.33393/grhta.2022.2340

• Cost-utility analysis of evolocumab in patients with ASCVD in Italy

  Andrea Marcellusi, Chiara Bini, Maria Assunta Rotundo, Emanuela Arcangeli, Laura Martinez, Francesc Sorio Vilela, Francesco Saverio Mennini

  155-167

  DOI: https://doi.org/10.33393/grhta.2021.2255

• Evaluation of epidemiological and economic consequences due to the delay in treatment of hiv-positive patients caused by the covid-19 pandemic

  Andrea Marcellusi, Chiara Bini, Massimo Andreoni, Andrea Antinori, Francesco Saverio Mennini

  147-154

  DOI: https://doi.org/10.33393/grhta.2021.2279

• The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective

  Luis J. Pastor-Quirós, Edgar P. Correa-Díaz

  140-146

  DOI: https://doi.org/10.33393/grhta.2021.2273

• Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy

  Paolo Gisondi, Francesco Loconsole, Paola Raimondo, Roberto Ravasio

  120-130

  DOI: https://doi.org/10.33393/grhta.2021.2258

• Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population

  Filippo Rumi, Michele Basile, Americo Cicchetti

  105-113

  DOI: https://doi.org/10.33393/grhta.2021.2247

• Budget Impact Analysis of prolonged-release buprenorphine depot-formulation for the management of patients affected by opioid use disorder

  Michele Basile, Lorenzo Somaini, Americo Cicchetti

  96-104

  DOI: https://doi.org/10.33393/grhta.2021.2237

• Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia

  Michele Basile, Filippo Rumi, Americo Cicchetti

  87-95

  DOI: https://doi.org/10.33393/grhta.2021.2238